2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Supportive Care, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Women’s Health, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

6139 Healthcare system costs with marstacimab and other therapies for the treatment of hemophilia in the United States

Guy Young, MD, Harika Booragadda, MPH2, Maria Gheorghe, PhD3, Carlos Estevez, MD4, Nathashi Jayawardena, MSc5, Allen Zhou6
1 University of Southern California, Los Angeles, California, United States
2 Pfizer, Inc, New York, New York, United States
3 Pfizer, Inc, Bucharest, Romania
4 Pfizer, Inc, New York, New York, United States
5 EVERSANA, Burlington, Ontario, Canada
6 EVERSANA, Burlington, Ontario, Canada

Introduction: Contemporary treatment options for patients living with hemophilia in the United States include extended half-life (EHL) factor therapies (for patients without inhibitors), bypassing agents (for patients with inhibitors), and novel non-factor therapies. Marstacimab is a human monoclonal antibody that targets tissue factor pathway inhibitor and is approved in the United States (US) for routine prophylaxis to prevent or reduce bleeding episodes in patients 6 years of age and older living with hemophilia A or B with and without inhibitors. This study evaluates the healthcare system costs of hemophilia treatment with different options.  Methods: An economic analysis was conducted to determine the annual costs per patient from ages 6 to 80 with different treatment options for hemophilia. Costs included product acquisition, acute bleed management, product administration, healthcare resource use, and adverse events. The analysis was separated into hemophilia A without inhibitors, hemophilia A with inhibitors, hemophilia B without inhibitors, and hemophilia B with inhibitors because of differences in treatment options available for each subpopulation. A US commercial payer perspective was adopted, with product acquisition costs based on June 2026 wholesale acquisition costs (WACs). Patient weights were based on age-specific National Health and Nutrition Examination Survey (NHANES) averages, and dosing was derived from Food and Drug Administration (FDA) prescribing information. Injectable products were assumed to have no vial sharing and included wastage, except for concizumab. Efficacy data to inform acute bleed management requirements were obtained from clinical trials for marstacimab and indirect treatment comparisons against other novel non-factor therapies. Acute bleed management costs were derived from efficacy data, dosing of factor replacement or bypassing agents as specified in FDA prescribing information, and product WACs. Healthcare resource costs included hospitalizations, emergency room visits, intensive care unit stays, specialist visits, outpatient consultations, and treatment-specific monitoring costs derived from literature, databases, and the Practice Management Information Corporation (PMIC) Medical Fees Directory. Results: In all populations, marstacimab was associated with the lowest annual costs per patient. In hemophilia A without inhibitors, marstacimab resulted in per patient average annual savings of $527,040 vs efanesoctocog alfa; $332,734 vs other EHLs; $46,455 vs emicizumab; $409,733 vs concizumab; $459,366 vs fitusiran; and $28,815 vs on-demand. This resulted in substantial cumulative lifetime cost savings ranging from $2,161,104 vs on-demand to $39,528,024 vs efanesoctocog alfa. In hemophilia A with inhibitors, marstacimab resulted in average annual savings of $175,406 vs emicizumab; $612,240 vs concizumab; $283,879 vs fitusiran; $3,410,808 vs anti-inhibitor coagulant complex prophylaxis; and up to $832,758 vs on-demand. This resulted in cumulative lifetime cost savings ranging from $13,155,443 vs emicizumab to $255,810,622 vs anti-inhibitor coagulant complex prophylaxis. In hemophilia B without inhibitors, marstacimab’s average annual cost savings were $144,106 vs EHL; $409,733 vs concizumab; $490,141 vs fitusiran; and $118,805 vs on-demand, with cumulative lifetime savings ranging from $8,910,391 vs on-demand to $33,819,746 vs fitusiran. In hemophilia B with inhibitors marstacimab’s cost savings were $639,831 vs concizumab; $284,903 vs fitusiran; and up to $832,218 vs on-demand, with cumulative lifetime savings ranging from $19,658,303 vs fitusiran to $62,416,344 vs coagulation Factor VIIa, recombinant on-demand. A sensitivity analysis that only included routine prophylaxis costs demonstrated similar trends and highlighted that product acquisition costs were the primary contributor to total healthcare system costs. Conclusion: For ages 6+ including hemophilia A and B, non-inhibitors and inhibitors, marstacimab was associated with the lowest average annual and cumulative healthcare system costs out of all treatment options. Product acquisition costs associated with prophylaxis were generally the primary contributor to total costs. Bleed management costs also contributed to total costs, with therapies associated with higher bleed-related resource utilization generating substantially greater annual and lifetime expenditures.

Harika Booragadda, MPH: Pfizer - Current equity holder in publicly-traded company; Pfizer - Stock (publicly traded); Pfizer - Current Employment